The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2013
DOI: 10.1016/j.critrevonc.2012.07.006
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of metastatic cervical cancer: Future directions involving targeted agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
54
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 70 publications
(55 citation statements)
references
References 99 publications
(94 reference statements)
1
54
0
Order By: Relevance
“…Cervical cancer is a key factor associated with morbidity and mortality in women worldwide (1). Infection with human papilloma viruses (HPV) triggers carcinogenesis.…”
Section: Introductionmentioning
confidence: 99%
“…Cervical cancer is a key factor associated with morbidity and mortality in women worldwide (1). Infection with human papilloma viruses (HPV) triggers carcinogenesis.…”
Section: Introductionmentioning
confidence: 99%
“…10 Diallyl disulfide (DADS; ie, CH2DCH-CH2-S-S-CH2-CHDCH2), an oil-soluble compound extracted from garlic (Allium sativum L.) documents as a potent compound to prevent cancer, genotoxicity, nephrotoxicity, and hepatotoxicity. 11,12 Although DADS has been reported to provide the anticancer activity in several cancer types by inhibiting cell cycle arrest and inducing apoptosis, 13,14 the molecular effect of DADS on high-LET carbon beams -regulated proliferation, cell cycle arrest and cell death is currently unknown.…”
Section: Introductionmentioning
confidence: 99%
“…Despite advances in screening, vaccination and treatment of early stage disease, a proportion of patients will be diagnosed with advanced stage (stage IVB), recurrent or persistent cervical cancer. Specifically, patients with International Federation of Obstetrics and Gynecology (FIGO) stage IB-IIA disease have a recurrence risk ranging from 10% to 20% despite primary chemo-radiation, while those patients diagnosed FIGO stage IIB-IVA have a 50% to 70% chance of disease recurrence [3]. For this subset of patients, systemic chemotherapy remains the standard treatment.…”
Section: Introductionmentioning
confidence: 99%